Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Notice of Effectiveness · EFFECT

Lexeo Therapeutics, Inc.

LXEONASDAQEQUITYCurrent

Notice of Effectiveness

Filed Nov 4, 2026Accepted Nov 5, 2026, 12:15 AM ESTFiling CIK 1907108Accession 9999999995-26-003444
Share

Structured filing — EFFECT

primary_doc.xml

Open full document ↗

Notice details

Submission type
EFFECT
Act
33

Effectiveness

Effective date
2026-11-04
Effective time (as filed)
16:00:00
Form
S-3

Registrant 1

Registrant
Lexeo Therapeutics, Inc.
Registrant CIK
0001907108
File number
333-299689

Company context

Lexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for PKP2-ACM, and others in devastating diseases with high unmet need.

Current securities

Recent company filings

  1. 4 filingNov 17, 2026
  2. 3 filingNov 17, 2026
  3. SCHEDULE 13G/A - filed by ORBIMED ADVISORS LLC regarding Lexeo Therapeutics, Inc.Nov 16, 2026
  4. 10-Q filingNov 16, 2026
  5. Results of Operations and Financial Condition · Regulation FD Disclosure · Other EventsNov 16, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.